Vimarsana
Biggest News Aggregation in the World

Page 6 - Vasculitis Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vasculitis Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vasculitis Foundation Today - Breaking & Trending Today

ChemoCentryx Reports Results of FDA Meeting on Avacopan | #site_titleChemoCentryx Reports Results of FDA Meeting on Avacopan - Vimarsana News

ChemoCentryx Reports Results of FDA Meeting on Avacopan | #site_titleChemoCentryx Reports Results of FDA Meeting on Avacopan

Posted on 2969 ChemoCentryx, Inc. (NASDAQ: CCXI)reported the outcome of the United States Food and Drug Administration Arthritis Advisory Committee on avacopan to treat Antineutrophil Cytoplasmic Autoantibody associated vasculitis.  In the final segment of the meetingthe committee voted on three questions present by the FDA: -The Committee vote split 9-9 on the first question, whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV (granulomatosis with polyangiitis (GPA) and microscopic ...

Iowa State professor Hector Avalos leaves legacy in multiple communities - Vimarsana News

Iowa State professor Hector Avalos leaves legacy in multiple communities

Hector Avalos' life included many experiences with death and dying because of his personal battles with disease.  But Avalos defined his life by what he could achieve in the time he had. The longtime professor at Iowa State University left a big imprint. Lucía Suárez, director of the Latino/a Studies Program at ISU, told the Tribune that Avalos was "the kind of professor that we all wish we were, and that we hope that we are.” She described him as generous, positive and thoughtful. Avalos founded the Latino/a Studies Program in the 1990s, was a renowned religious studies scholar and a ...

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis - Vimarsana News

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis

Search jobs 16-Dec-2020 First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis New clinical trial also announced for Fasenra in eosinophilic gastritis/eosinophilic gastroenteritis The first patients have been dosed in Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with polyangiitis (EGPA) AstraZeneca will al...